Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Leases (2016 - 2024)

Niagen Bioscience (NAGE) has disclosed Capital Leases for 12 consecutive years, with $2000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Capital Leases fell 85.71% to $2000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $2000.0, a 85.71% decrease, with the full-year FY2023 number at $12000.0, down 45.45% from a year prior.
  • Capital Leases was $2000.0 for Q3 2024 at Niagen Bioscience, down from $6000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $36000.0 in Q1 2020 to a low of $2000.0 in Q3 2024.
  • A 5-year average of $16076.9 and a median of $14000.0 in 2023 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: rose 11.11% in 2020, then plummeted 85.71% in 2024.
  • Niagen Bioscience's Capital Leases stood at $20000.0 in 2020, then plummeted by 45.0% to $11000.0 in 2021, then surged by 100.0% to $22000.0 in 2022, then crashed by 45.45% to $12000.0 in 2023, then tumbled by 83.33% to $2000.0 in 2024.
  • Per Business Quant, the three most recent readings for NAGE's Capital Leases are $2000.0 (Q3 2024), $6000.0 (Q2 2024), and $9000.0 (Q1 2024).